https://www.selleckchem.com/pr....oducts/tiplaxtinin-p
83-9.47) in the group receiving JD Granule and 8 months (95% CI 6.67-9.8 in the group receiving sorafenib, with half-, 1- and 2-year survival rates of 53.6%, 31.2% and 13.2% vs 60.1%, 35.5% and 14.2%, respectively. Even after PSM, the median survival time did not differ between the JD Granule group (9.03 months; 95% CI 6.37-14.2) and the sorafenib group (7.93 months; 95% CI 6.5-9.97), with comparable half-, 1- and 2-year survival rates. The most common adverse events (AEs) were diarrhea (13.7%) and fatigue (5.6%) in the JD
Мне нравится
Комментарий
Перепост
